SC
CRDF icon

Scholtz & Company’s Cardiff Oncology CRDF Stock Holding History

Scholtz & Company’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,625
Closed -$111K – 63
2021
Q3 		$111K Buy
+16,625
New +$104K 0.04% 67
2021
Q1 		– Sell
-36,125
Closed -$650K – 73
2020
Q4 		$650K Sell
36,125
-700
-2% -$12.3K 0.25% 51
2020
Q3 		$523K Sell
36,825
-125
-0.3% -$825 0.23% 51
2020
Q2 		$185K Buy
+36,950
New +$75.6K 0.09% 58

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Scholtz & Company's CRDF Position: Q4 2021 in Review

Scholtz & Company sold out of Cardiff Oncology (CRDF) in Q4 2021, closing a stake of 16,625 shares — an estimated $111K sold.

Scholtz & Company first reported a position in CRDF in Q2 2020 and held it in 4 quarters. The position peaked at $650K in Q4 2020. 87 funds tracked by Wall St. Rank hold CRDF as of Q4 2021.

  • Scholtz & Company reported no remaining Cardiff Oncology position as of Q4 2021 after selling out during the quarter.
  • Scholtz & Company sold 16,625 Cardiff Oncology shares in Q4 2021, an estimated $111K.
  • Scholtz & Company first reported a position in Cardiff Oncology in Q2 2020 and held it in 4 quarters.
  • Scholtz & Company's Cardiff Oncology position peaked at $650K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2021.

Based on Scholtz & Company's 13F filing for Q4 2021, filed 15 Feb 2022.